Home » Pipeline
Pipeline
December 8, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
UCART22 |
relapsed/refractory B-cell acute lymphoblastic leukemia |
Phase 1 trial initiated in subjects at the University of Texas MD Anderson Cancer Center |
|
IBI315 |
HER2-expressing advanced solid malignancies |
Phase 1 trial initiated enrolling subjects at sites in China |
|
voriconazole |
antifungal drug for treating Invasive Pulmonary Aspergillosis |
Phase 1 trial initiated enrolling 64 healthy subjects at one site in Canada |
|
XPro1595 |
Alzheimer's disease |
Phase 1b trial initiated in 18 subjects with Alzheimer’s disease at multiple sites in England and Australia |
|
tigilanol tiglate |
head and neck cancer |
Phase 1/2 trial initiated in 40 subjects with head and neck squamous cell carcinoma (HNSCC) in at least four sites in India and Australia |
|
SX600 |
sciatica |
Phase 1/2 trial initiated enrolling subjects |
|
CVN424 |
Parkinson’s disease |
Phase 2 trial initiated in 70 subjects with Parkinson’s disease and motor fluctuations who are currently being treated with levodopa |
|
Zilucoplan |
immune-mediated necrotizing myopathy |
Phase 2 trial initiated dosing 24 subjects with IMNM who are positive for anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase or anti-signal recognition particle autoantibodies |
|
EscharEx |
venous leg ulcers |
Phase 2 trial initiated enrolling 174 subjects at 25 sites |
|
cerdulatinib |
vitiligo and atopic dermatitis |
Phase 2a trial initiated enrolling 30 subjects aged 18-70 years old diagnosed with vitiligo |
|
TD-8236 |
inflammatory lung diseases |
Phase 2 trial initiated enrolling 21 subjects with mild asthma following an inhaled allergen challenge |
|
CPI-613 |
Burkitt’s lymphoma and leukemia |
Phase 2 expansion trial initiated enrolling subjects at Massachusetts General Hospital in Boston |
|
AG013 |
oral mucositis |
Phase 2 trial initiated enrolling 200 subjects undergoing traditional chemoradiation for the treatment of head and neck cancer |
|
CTP-692 |
schizophrenia |
Phase 2 trial initiated enrolling 300 adult subjects with schizophrenia who are stable on an antipsychotic medication |
|
SGX301 |
cutaneous T-cell lymphoma |
Phase 3 trial initiated enrolling 169 subjects at multiple centers |
|
vonoprazan |
erosive esophagitis and heartburn |
Phase 3 trial initiated enrolling 1,000 subjects with EE at multiple centers in the U.S. and Europe |
|
PLX-PAD cells |
muscle regeneration |
Phase 3 trial initiated enrolling 240 subjects recovering from arthroplasty for hip fracture at multiple sites in the U.S., Europe and Israel |
|
Entervax |
Fever |
Clinical trial authorization granted by the MHRA |
|
SKL24741 |
epilepsy |
IND approval granted by the FDA |
|
BAT2206 |
psoriatic arthritis |
IND approval granted by the FDA |
|
PGDx elio |
cancer |
IDE approval granted by FDA |
|
Carafate |
duodenal ulcer |
Abbreviated NDA granted by the FDA |
|
N-803 (IL-15) super antagonist |
non-muscle invasive bladder cancer |
Breakthrough device designation granted by the FDA |
|
Bortezomib |
intravenous use only for the treatment of adult patients with multiple myeloma and for the treatment of mantle cell lymphoma |
Approval granted by the FDA |
|
Tula system |
placement of tympanostomy tubes (commonly known as ear tubes) in the physician’s office without general anesthesia |
Approval granted by the FDA |
|
Tecentriq plus chemotherapy |
metastatic non-squamous non-small cell lung cancer |
Approval granted by the FDA |
|
FoundationOne CDx as a Companion Diagnostic for Piqray (alpelisib) |
hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer |
Approval granted by the FDA |
Upcoming Events
-
21Oct
